BJERKHOLT ERIC 4

What Happened

• Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals (MIRM), sold a total of 5,000 shares in open-market transactions on July 6, 2026, generating approximately $611,274 in proceeds. The sales were executed in four tranches: 3,124 shares at $121.67 ($380,097), 1,048 shares at $122.43 ($128,307), 528 shares at $123.84 ($65,388), and 300 shares at $124.94 ($37,482). These were disposals (sales), which are typically routine cash-management transactions rather than direct buy signals.

Key Details

• Transaction date: July 6, 2026; Form 4 filed July 8, 2026 (timely filing).
• Trade breakdown: 3,124 @ $121.67; 1,048 @ $122.43; 528 @ $123.84; 300 @ $124.94; total ≈ $611,274.
• Shares owned after transaction: Not disclosed in the filing.
• Notable footnotes: Transactions were made pursuant to a Rule 10b5-1 trading plan adopted March 9, 2026 (pre-arranged plan). The filing provides weighted-average prices and price ranges for the reported tranches and notes full per-price breakdowns are available upon request to the SEC, issuer, or shareholders.
• Transaction code: S = Sale.

Context

• 10b5-1 plans allow insiders to sell shares according to a pre-set schedule and are commonly used to avoid allegations of opportunistic timing; such sales are usually viewed as routine and should not be taken alone as a signal of company prospects. Purchases by insiders tend to carry more weight for bullish interpretation.